{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Patel S"],"funding":["NIGMS NIH HHS"],"pagination":["304-309"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12797327"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["Enantioenriched sulfinamides serve as key intermediates for the asymmetric synthesis of sulfoximines and other S(VI) pharmacophores. Enantioselective biocatalytic oxidation of an <i>S</i>-methyl sulfenamide to the corresponding <i>S</i>-methyl sulfinamide proceeds in good yield and >99:1 er. Its utility as a key chiral intermediate was demonstrated by stereoretentive <i>S</i>-arylation and <i>S</i>-alkylation as well as by the asymmetric synthesis of two <i>S</i>-methyl sulfoximine drug candidates, with <i>S</i>-methyl substitution notably present in most sulfoximine clinical candidates."],"journal":["Organic letters"],"pubmed_title":["Biocatalytic Enantioselective Oxidation of &lt;i&gt;N&lt;/i&gt;-Acyl-&lt;i&gt;S&lt;/i&gt;-Methyl Sulfenamides for the Asymmetric Synthesis of &lt;i&gt;S&lt;/i&gt;-Methyl Sulfoximines."],"pmcid":["PMC12797327"],"funding_grant_id":["R35 GM122473"],"pubmed_authors":["Finnigan JD","Greenwood NS","Patel S","Ellman JA","Lim J"],"additional_accession":[]},"is_claimable":false,"name":"Biocatalytic Enantioselective Oxidation of &lt;i&gt;N&lt;/i&gt;-Acyl-&lt;i&gt;S&lt;/i&gt;-Methyl Sulfenamides for the Asymmetric Synthesis of &lt;i&gt;S&lt;/i&gt;-Methyl Sulfoximines.","description":"Enantioenriched sulfinamides serve as key intermediates for the asymmetric synthesis of sulfoximines and other S(VI) pharmacophores. Enantioselective biocatalytic oxidation of an <i>S</i>-methyl sulfenamide to the corresponding <i>S</i>-methyl sulfinamide proceeds in good yield and >99:1 er. Its utility as a key chiral intermediate was demonstrated by stereoretentive <i>S</i>-arylation and <i>S</i>-alkylation as well as by the asymmetric synthesis of two <i>S</i>-methyl sulfoximine drug candidates, with <i>S</i>-methyl substitution notably present in most sulfoximine clinical candidates.","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T15:27:51.949Z","creation":"2026-06-01T03:10:54.096Z"},"accession":"S-EPMC12797327","cross_references":{"pubmed":["41420268"],"doi":["10.1021/acs.orglett.5c04701"]}}